OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule

by admin | 29th August 2023 | News

New York and London, August 29,  2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the...

Recent Posts

  • OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
  • OKYO Pharma Announces Chairman and CEO Acquire Shares
  • OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
  • OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
  • OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023